Cancer History ProjectConversation with The Cancer LetterFree Craig Jordan on discovering tamoxifen’s role in breast cancer—and a lifetime of innovation November 11, 2022Vol.48 No.41By Alexandria Carolan
Clinical Roundup VCU Massey scientists pinpoint druggable target in TNBC October 28, 2022Vol.48 No.39
Drugs & Targets Jazz Pharmaceuticals and Zymeworks agree to develop, commercialize zanidatamab October 21, 2022Vol.48 No.38
In Brief NCI awards five-year, $13.3M grant for collaborative study on sequential combinations of targeted inhibitors, immunotherapies September 16, 2022Vol.48 No.33
Drugs & Targets Indivumed and CELLphenomics form partnership for improved patient care in EU-funded project September 16, 2022Vol.48 No.33
Drugs & Targets FDA approves first targeted therapy for HER2-low breast cancer September 09, 2022Vol.48 No.32
Drugs & Targets FDA grants accelerated approval to Enhertu for HER2-mutant NSCLC and companion diagnostic September 09, 2022Vol.48 No.32
Drugs & Targets FDA approves Incyte’s Pemazyre as first and only targeted treatment for myeloid/lymphoid neoplasms with FGFR1 rearrangement September 09, 2022Vol.48 No.32
Drugs & Targets FDA approves Tabrecta for metastatic NSCLC with mesenchymal-epithelial transition exon 14 skipping September 09, 2022Vol.48 No.32
Guest Editorial ASCO’s “rock concert” moments came 17 years apart—in 2005 and 2022DESTINY-04 results extend HER2-targeted therapy to a larger population in breast cancer June 10, 2022Vol.48 No.23By George W. Sledge Jr.
